肺动脉高压的新型治疗方法
Novel Therapeutic Approaches of Pulmonary Arterial Hypertension.
作者信息
Tyagi Sanjay, Batra Vishal
机构信息
Department of Cardiology, Maulana Azad Medical College, New Delhi, India.
Department of Cardiology, G.B. Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
出版信息
Int J Angiol. 2019 Jun;28(2):112-117. doi: 10.1055/s-0039-1692140. Epub 2019 Jul 12.
Abstract
Pulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.
摘要
肺动脉高压（PAH）是一种罕见的疾病，其特征是肺血管进行性重塑。尽管在过去二十年中PAH的治疗有所改善，但结果仍然是致命的。目前，PAH的治疗针对三个已确立的途径：一氧化氮（NO）途径、内皮素受体和前列腺素。PAH中有多个新药开发的潜在靶点，这需要细致的研究和临床试验。
相似文献
1
Novel Therapeutic Approaches of Pulmonary Arterial Hypertension.肺动脉高压的新型治疗方法
Int J Angiol. 2019 Jun;28(2):112-117. doi: 10.1055/s-0039-1692140. Epub 2019 Jul 12.
2
Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.肺动脉高压中的信号通路与药物——聚焦内皮素受体拮抗剂的作用
Cardiovasc Drugs Ther. 2015;29(5):469-79. doi: 10.1007/s10557-015-6605-6.
3
Current drug targets and future therapy of pulmonary arterial hypertension.肺动脉高压的当前药物靶点与未来治疗
Curr Med Chem. 2007;14(6):719-33. doi: 10.2174/092986707780059562.
4
Inhalation therapy to treat pulmonary arterial hypertension.吸入疗法治疗肺动脉高压。
Pharm Pat Anal. 2012 Nov;1(5):577-88. doi: 10.4155/ppa.12.66.
5
New Drugs and Therapies in Pulmonary Arterial Hypertension.新型药物和疗法在肺动脉高压中的应用。
Int J Mol Sci. 2023 Mar 19;24(6):5850. doi: 10.3390/ijms24065850.
6
Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.儿童肺动脉高压的治疗。小儿肺动脉高压诊断与治疗专家共识声明。欧洲儿科肺血管疾病网络，经国际心脏和肺移植学会（ISHLT）及德国心肺协会（DGPK）认可。
Heart. 2016 May;102 Suppl 2:ii67-85. doi: 10.1136/heartjnl-2015-309103.
7
Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.肺动脉高压治疗的新策略
Curr Drug Targets. 2016;17(7):817-23. doi: 10.2174/1389450116666150722140424.
8
Targeted therapies in pulmonary arterial hypertension.肺动脉高压的靶向治疗。
Pharmacol Ther. 2014 Feb;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002. Epub 2013 Oct 14.
9
Current therapies for pulmonary arterial hypertension.肺动脉高压的现有疗法。
Semin Cardiothorac Vasc Anesth. 2007 Jun;11(2):137-48. doi: 10.1177/1089253207301356.
10
Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.腺苷受体作为治疗肺动脉高压的药物靶点
Front Pharmacol. 2017 Dec 4;8:858. doi: 10.3389/fphar.2017.00858. eCollection 2017.
引用本文的文献
1
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension.肺动脉高压大鼠模型右心室功能的综合超声心动图评估。
J Vis Exp. 2023 Jan 20(191). doi: 10.3791/63775.
2
Schistosome-Associated Pulmonary Arterial Hypertension: A Review Emphasizing Pathogenesis.血吸虫相关性肺动脉高压：一篇着重于发病机制的综述
Front Cardiovasc Med. 2021 Oct 5;8:724254. doi: 10.3389/fcvm.2021.724254. eCollection 2021.
本文引用的文献
1
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.
2
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.血流动力学定义和肺动脉高压的最新临床分类。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
3
Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.膜结合型 IL6R 的异位上调驱动肺动脉高压中的血管重构。
J Clin Invest. 2018 May 1;128(5):1956-1970. doi: 10.1172/JCI96462. Epub 2018 Apr 9.
4
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.系统性硬皮病患者肺动脉高压的发生率及相关影响因素。
Eur Respir J. 2018 Apr 4;51(4). doi: 10.1183/13993003.01197-2017. Print 2018 Apr.
5
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.索特西普长期扩展治疗低危骨髓增生异常综合征患者贫血：一项2期剂量范围试验
Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.
6
ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.ASK1 抑制剂可阻止肺动脉高压临床前模型中的疾病进展。
Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. doi: 10.1164/rccm.201703-0502OC.
7
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.随机安慰剂对照安全性和耐受性试验的 FK506（他克莫司）治疗肺动脉高压。
Eur Respir J. 2017 Sep 11;50(3). doi: 10.1183/13993003.02449-2016. Print 2017 Sep.
8
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.HDAC6：一种新型组蛋白去乙酰化酶与肺动脉高压相关。
Sci Rep. 2017 Jul 3;7(1):4546. doi: 10.1038/s41598-017-04874-4.
9
Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.肺动脉高压领域的转化医学进展。肺动脉高压中微小RNA生物学的转化。这需要的不仅仅是“miR”这个词。
Am J Respir Crit Care Med. 2017 Jan 15;195(2):167-178. doi: 10.1164/rccm.201604-0886PP.
10
Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study.比索洛尔治疗特发性肺动脉高压：一项探索性研究。
Eur Respir J. 2016 Sep;48(3):787-96. doi: 10.1183/13993003.00090-2016. Epub 2016 Jul 7.
Zotero 插件